Duke's Califf Tapped For FDA Deputy Post; Some See Succession Planning
This article was originally published in The Gray Sheet
Robert Califf will join FDA in February as deputy commissioner for medical products and tobacco. He may be being groomed to become the next commissioner, agency watchers suggest.
You may also be interested in...
FDA Commissioner says every day at the agency is fun, but the decision to remain will be made by the next president.
The Senate confirmed Robert Califf as the new FDA commissioner after months of delay, giving the cardiologist, clinical trial expert and established agency official a better platform to push his priorities, which include combination product and clinical data-collection reforms, while implementing projects already under way.
Groups including Public Citizen say the Senate should reject the president's nomination of clinical trials expert and cardiologist Robert Califf as FDA commissioner due to his prior financial ties to industry. "The Gray Sheet" takes a look at his financial conflict of interest forms from former employer Duke University, which show relationships with a range of manufacturers – although more are from the pharmaceutical arena than the medical device space. But entries in Duke University’s conflict-of-interest disclosures don't always match up to those in the government's Open Payments database.